| Symbol | INDP |
|---|---|
| Name | INDAPTUS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | THREE COLUMBUS CIRCLE,15TH FLOOR, NEW YORK, New York, 10019, United States |
| Telephone | 646) 427-2727 |
| Fax | — |
| — | |
| Website | https://www.indaptusrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001857044 |
| Description | Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Additional info from NASDAQ: |
(30% Negative) INDAPTUS THERAPEUTICS, INC. (INDP) Reports Q2 2026 Financial Results
Read moreIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Read moreNew Form SCHEDULE 13D/A - Indaptus Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001829126-26-004104 <b>Size:</b> 21 KB
Read moreNew Form 8-K/A - Indaptus Therapeutics, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001493152-26-018954 <b>Size:</b> 223 KB <br />Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers <br />Ite…
Read more(99% Neutral) INDAPTUS THERAPEUTICS, INC. (INDP) Announces New Board Appointment
Read moreNew Form 3 - Indaptus Therapeutics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001829126-26-003665 <b>Size:</b> 3 KB
Read moreNew Form SCHEDULE 13G/A - Indaptus Therapeutics, Inc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001104659-26-039973 <b>Size:</b> 16 KB
Read more(99% Neutral) INDAPTUS THERAPEUTICS, INC. (INDP) Announces New Board Appointment
Read moreNew Form 3 - Indaptus Therapeutics, Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001493152-26-015004 <b>Size:</b> 4 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid T… | Phase1 | Solid Tumor, Adult | Active_Not_Recruiting | 2023-02-28 | 2027-09-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tislelizumab | Other | Phase PHASE1 | Solid Tumor, Adult | ACTIVE_NOT_RECRUITING | NCT05651022 |
| Decoy20 | Other | Phase PHASE1 | Solid Tumor, Adult | ACTIVE_NOT_RECRUITING | NCT05651022 |
| Tislelizumab | DRUG | Phase PHASE1 | Solid Tumor, Adult | ACTIVE_NOT_RECRUITING | NCT05651022 |
| Decoy20 | DRUG | Phase PHASE1 | Solid Tumor, Adult | ACTIVE_NOT_RECRUITING | NCT05651022 |